Nevro (NVRO)
(Delayed Data from NYSE)
$9.79 USD
-0.72 (-6.85%)
Updated May 10, 2024 04:00 PM ET
After-Market: $9.79 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Nevro (NVRO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$17.85 | $40.00 | $10.00 | 69.84% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Nevro comes to $17.85. The forecasts range from a low of $10.00 to a high of $40.00. The average price target represents an increase of 69.84% from the last closing price of $10.51.
Analyst Price Targets (13)
Broker Rating
Nevro currently has an average brokerage recommendation (ABR) of 3.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 3.13 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, one is Strong Buy, representing 6.67% of all recommendations. A month ago, Strong Buy represented 6.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 11 | 11 | 11 | 11 | 10 |
Sell | 2 | 2 | 2 | 2 | 2 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 3.13 | 3.13 | 3.13 | 3.13 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/8/2024 | Canaccord Genuity | William J Plovanic | Hold | Hold |
5/8/2024 | Piper Sandler | Adam C Maeder | Strong Sell | Strong Sell |
5/8/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/7/2024 | William Blair | Brandon Vazquez | Hold | Hold |
4/11/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Hold |
2/22/2024 | Robert W. Baird & Co. | David Rescott | Hold | Hold |
8/2/2023 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.13 |
ABR (Last week) | 3.13 |
# of Recs in ABR | 15 |
Average Target Price | $17.85 |
LT Growth Rate | 16.10% |
Industry | Medical - Instruments |
Industry Rank by ABR | 95 of 252 |
Current Quarter EPS Est: | -0.68 |